Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Código da empresaVALN
Nome da EmpresaValneva SE
Data de listagemJun 28, 2007
Fundado em1999
CEOMr. Thomas Lingelbach
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 28
Endereço6 rue Alain Bombard
CidadeSAINT-HERBLAIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísFrance
Código postal44800
Telefone33228073710
Sitehttps://valneva.com/
Código da empresaVALN
Data de listagemJun 28, 2007
Fundado em1999
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados